Tissue-Engineered Skin Substitutes

Nyame, Theodore T.; Chiang, H. Abraham; Leavitt, Tripp; Ozambela, Manuel; Orgill, Dennis P.

doi:10.1097/prs.0000000000001748

Cited by 74 publications

(44 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to denovoSkin, the cells are from allogeneic origin [23]. The product Dermagraft® (Organogenesis Inc.) consists of allogeneic fibroblasts in a polyglactin matrix and is used for the treatment of diabetic foot ulcers [24]. Epicel® (Vericel, Cambridge, MA, USA) consists of autologous keratinocytes and is used for the treatment of large burns [24].…”

Section: Advanced Therapy Medicinal Products (Atmps)mentioning

confidence: 99%

“…The product Dermagraft® (Organogenesis Inc.) consists of allogeneic fibroblasts in a polyglactin matrix and is used for the treatment of diabetic foot ulcers [24]. Epicel® (Vericel, Cambridge, MA, USA) consists of autologous keratinocytes and is used for the treatment of large burns [24]. Currently in a phase II trial is the product Tiscover® (A-SKIN, Amsterdam, The Netherlands) for the treatment of chronic wounds, consisting of autologous keratinocytes and fibroblasts.…”

Section: Advanced Therapy Medicinal Products (Atmps)mentioning

confidence: 99%

See 1 more Smart Citation

About ATMPs, SOPs and GMP: The Hurdles to Produce Novel Skin Grafts for Clinical Use

Hartmann-Fritsch

Marino

Ernst

2016

Transfus Med Hemother

View full text Add to dashboard Cite

Background: The treatment of severe full-thickness skin defects represents a significant and common clinical problem worldwide. A bio-engineered autologous skin substitute would significantly reduce the problems observed with today's gold standard. Methods: Within 15 years of research, the Tissue Biology Research Unit of the University Children's Hospital Zurich has developed autologous tissue-engineered skin grafts based on collagen type I hydrogels. Those products are considered as advanced therapy medicinal products (ATMPs) and are routinely produced for clinical trials in a clean room facility following the guidelines for good manufacturing practice (GMP). This article focuses on hurdles observed for the translation of ATMPs from research into the GMP environment and clinical application. Results and Conclusion: Personalized medicine in the field of rare diseases has great potential. However, ATMPs are mainly developed and promoted by academia, hospitals, and small companies, which face many obstacles such as high financial burdens.

show abstract

Section: Advanced Therapy Medicinal Products (Atmps)mentioning

confidence: 99%

Section: Advanced Therapy Medicinal Products (Atmps)mentioning

confidence: 99%

About ATMPs, SOPs and GMP: The Hurdles to Produce Novel Skin Grafts for Clinical Use

Hartmann-Fritsch

Marino

Ernst

2016

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…In this review, we discuss one of the above triads of tissue engineering, i.e., scaffold types, and materials used for the fabrication of scaffolds, their advantages and disadvantages, with a major focus on applications in skin tissue engineering. Several scaffolding approaches have been reported for their efficient use as suitable matrices to facilitate the growth and differentiation of skin cells [2,7,8,9]. In this paper, we review various scaffolding approaches, types of scaffolds and various biomaterials used in skin tissue engineering and wound regenerative medicine.…”

Section: Introductionmentioning

confidence: 99%

Future Prospects for Scaffolding Methods and Biomaterials in Skin Tissue Engineering: A Review

Chaudhari

Vig

Baganizi

et al. 2016

IJMS

466

288

View full text Add to dashboard Cite

Over centuries, the field of regenerative skin tissue engineering has had several advancements to facilitate faster wound healing and thereby restoration of skin. Skin tissue regeneration is mainly based on the use of suitable scaffold matrices. There are several scaffold types, such as porous, fibrous, microsphere, hydrogel, composite and acellular, etc., with discrete advantages and disadvantages. These scaffolds are either made up of highly biocompatible natural biomaterials, such as collagen, chitosan, etc., or synthetic materials, such as polycaprolactone (PCL), and poly-ethylene-glycol (PEG), etc. Composite scaffolds, which are a combination of natural or synthetic biomaterials, are highly biocompatible with improved tensile strength for effective skin tissue regeneration. Appropriate knowledge of the properties, advantages and disadvantages of various biomaterials and scaffolds will accelerate the production of suitable scaffolds for skin tissue regeneration applications. At the same time, emphasis on some of the leading challenges in the field of skin tissue engineering, such as cell interaction with scaffolds, faster cellular proliferation/differentiation, and vascularization of engineered tissues, is inevitable. In this review, we discuss various types of scaffolding approaches and biomaterials used in the field of skin tissue engineering and more importantly their future prospects in skin tissue regeneration efforts.

show abstract

“…However, STSG without adequate dermal support are prone to contraction and restrictive scarring, and are not suitable to cover poorly vascularized tissues [4]. These shortcomings led to the development of tissue-engineered dermal substitutes [5]. The porous structure of these matrices provides mechanical support and promotes cellular infiltration and vascular ingrowth from the surrounding host tissue [6].…”

Section: Introductionmentioning

confidence: 99%

The Crucial Role of Vascularization and Lymphangiogenesis in Skin Reconstruction

et al. 2018

View full text Add to dashboard Cite

Background: The treatment of extensive skin defects and bradytrophic wounds remains a challenge in clinical practice. Despite emerging tissue engineering approaches, skin grafts and dermal substitutes are still the routine procedure for the majority of skin defects. Here, we review the role of vascularization and lymphangiogenesis for skin grafting and dermal substitutes from the clinician’s perspective. Summary: Graft revascularization is a dynamic combination of inosculation, angiogenesis, and vasculogenesis. The majority of a graft’s microvasculature regresses and is replaced by ingrowing microvessels from the wound bed, finally resulting in a chimeric microvascular network. After inosculation within 48–72 h, the graft is re-oxygenated. In contrast to skin grafts, the vascularization of dermal substitutes is slow and dependent on the ingrowth of vessel-forming angiogenic cells. Preclinical angiogenic strategies with adipose tissue-derived isolates are appealing for the treatment of difficult wounds and may markedly accelerate skin reconstruction in the future. However, their translation from bench to bedside is still restricted by major regulatory restrictions. Finally, the lymphatic system contributes to edema reduction and the removal of local wound debris. Therapeutic lymphangiogenesis is an emerging field of research in skin reconstruction. Key Messages: For the successful engraftment of skin grafts and dermal substitutes, the rapid formation of a microvascular network is of pivotal importance. Hence, to understand the biological processes behind revascularization of skin substitutes and to implement this knowledge into clinical practice is a prerequisite when treating skin defects. Furthermore, a functional lymphatic drainage crucially contributes to the engraftment of skin substitutes.

show abstract

Tissue-Engineered Skin Substitutes

Cited by 74 publications

References 6 publications

About ATMPs, SOPs and GMP: The Hurdles to Produce Novel Skin Grafts for Clinical Use

About ATMPs, SOPs and GMP: The Hurdles to Produce Novel Skin Grafts for Clinical Use

Future Prospects for Scaffolding Methods and Biomaterials in Skin Tissue Engineering: A Review

The Crucial Role of Vascularization and Lymphangiogenesis in Skin Reconstruction

Contact Info

Product

Resources

About